<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05792293</url>
  </required_header>
  <id_info>
    <org_study_id>FMASUMD45/2021</org_study_id>
    <nct_id>NCT05792293</nct_id>
  </id_info>
  <brief_title>Role of Statin Therapy in Prevention of Anthracycline-Induced Cardiotoxicity</brief_title>
  <official_title>Role of Statin Therapy in Prevention of Anthracycline-Induced Cardiotoxicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at evaluating the role of Atorvastatin in prevention of Anthracycline induced&#xD;
      cardiotoxicity&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study participants are female patients with breast cancer receiving Anthracycline based&#xD;
      chemotherapy.&#xD;
&#xD;
      They will be divided into 2 groups , the first group will receive 40 mg oral atorvastatin&#xD;
      through out the study , while the other group will receive a placebo.&#xD;
&#xD;
      Full echocardiographic study including 3D echocardiography will be done to all patients&#xD;
      before starting their chemotherapy and after 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Single blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of cancer therapy related cardiac dysfunction among the two groups</measure>
    <time_frame>Six months</time_frame>
    <description>cancer therapy related cardiac dysfunction defined as drop in ejection fraction more than 10% and to a value below 53% assessed by 3D echocardiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in left ventricular ejection fraction assessed by 3D echocardiography among the two groups</measure>
    <time_frame>Six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in left ventricular volumes assessed by 3D echocardiography among the two groups</measure>
    <time_frame>Six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in left ventricular diastolic function among the two groups</measure>
    <time_frame>Six months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Doxorubicin Induced Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fifty female patients diagnosed with breast cancer receiving Anthracycline based chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Fifty female patients diagnosed with breast cancer receiving Anthracycline based chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 40 Mg Oral Tablet</intervention_name>
    <description>40 mg oral dose of atorvastatin , lipid lowering drug with other pleotropic effects</description>
    <arm_group_label>Study Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female patients diagnosed with histology proven breast cancer with an indication to&#xD;
             primary systemic therapy or adjuvant regimens based on anthracyclines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with impaired LV systolic function (EF below 50%)&#xD;
&#xD;
          -  Patients with severe valvular heart disease&#xD;
&#xD;
          -  Patients previously diagnosed with coronary artery disease&#xD;
&#xD;
          -  Patients with baseline elevated liver enzymes&#xD;
&#xD;
          -  Patients with prior chemotherapy or radiation therapy&#xD;
&#xD;
          -  Pregnant females&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female patients diagnosed with breast cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed L Mohamed, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed L Mohamed, Master</last_name>
    <phone>+201141141677</phone>
    <email>Doc.ahmedlotfy91@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ain Shams University hospitals</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed L Mohamed, Master</last_name>
      <phone>+201141141677</phone>
      <email>Doc.ahmedlotfy91@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>March 19, 2023</study_first_submitted>
  <study_first_submitted_qc>March 19, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2023</study_first_posted>
  <last_update_submitted>April 4, 2023</last_update_submitted>
  <last_update_submitted_qc>April 4, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Ahmed Lotfy Mohamed</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Anthracyclines</keyword>
  <keyword>Doxorubuicn</keyword>
  <keyword>Cardiotoxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

